Gain Therapeutics (GANX) Net Cash Flow (2020 - 2026)
Gain Therapeutics (GANX) posted quarterly Net Cash Flow of -$4.3 million for Q1 2026, down 203.5% year-over-year from $4.2 million in Q1 2025, and down 136.23% quarter-over-quarter from $11.9 million in Q4 2025.
Gain Therapeutics (GANX) Net Cash Flow (2020 - 2026) Analysis & Trends
Gain Therapeutics' Net Cash Flow history runs 7 years deep, the most recent figure standing at -$4.3 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 203.5% year-over-year to -$4.3 million; the TTM figure through Mar 2026 stood at $7.1 million (up 544.1% YoY), while the FY2025 annual figure was $10.0 million, up 1228.91% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$4.3 million, down from $11.9 million in the prior quarter.
- The five-year high for Net Cash Flow was $11.9 million in Q4 2025, with the low at -$19.9 million in Q2 2022.
- The 5-year median for Net Cash Flow is -$1.4 million (2025), against an average of -$1.2 million.
- The sharpest annual moves came in 2022 and 2024: Net Cash Flow tumbled 477.38% in 2022, then surged 2741.25% in 2024.
- Gain Therapeutics' Net Cash Flow stood at -$3.8 million in 2022, then jumped by 285.69% to $7.0 million in 2023, then slumped by 116.83% to -$1.2 million in 2024, then surged by 1106.77% to $11.9 million in 2025, then tumbled by 136.23% to -$4.3 million in 2026.
- Business Quant data shows GANX's Net Cash Flow at -$4.3 million in Q1 2026, $11.9 million in Q4 2025, and $2.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Gain Therapeutics | 85.97 Mn | 85.97 Mn | - | -3.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.31 Mn |
| Jun 30, 2026 | -3.31 Mn |
| Mar 31, 2026 | -4.32 Mn |
| Mar 31, 2026 | -4.32 Mn |
| Dec 31, 2025 | 11.93 Mn |
| Dec 31, 2025 | 11.93 Mn |
| Sep 30, 2025 | 2.11 Mn |
| Sep 30, 2025 | 2.11 Mn |
| Jun 30, 2025 | -2.63 Mn |
| Jun 30, 2025 | -2.63 Mn |
| Mar 31, 2025 | -1.42 Mn |
| Mar 31, 2025 | -1.42 Mn |
| Dec 31, 2024 | -1.19 Mn |
| Dec 31, 2024 | -1.19 Mn |
| Sep 30, 2024 | -5.27 Mn |
| Sep 30, 2024 | -5.27 Mn |
| Jun 30, 2024 | 6.28 Mn |
| Jun 30, 2024 | 6.28 Mn |
| Mar 31, 2024 | -713,636.00 |
| Mar 31, 2024 | -713,636.00 |